Skip to main content
SpringerLink
Log in

Hemophilia

  • Chapter
  • First Online:
Benign Hematologic Disorders in Children

  • 758 Accesses

Abstract

Hemophilia is a set of disorders caused by deficiency of blood clotting proteins. This chapter will focus on hemophilia A and B, the two most common severe bleeding disorders, resulting from deficiency of coagulation factor VIII and IX, respectively. Hemophilia affects more than 20,000 people in the United States. Bleeding in hemophilia is most often into the joints but can include life-threatening bleeding such as central nervous system bleeding. Treatment has advanced considerably over the past 50 years, and this chapter highlights the advances in treatment and the use of prophylactic agents to prevent bleeding.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mannucci PM, Tuddenham EGD. The hemophilias – from royal genes to gene therapy. N Engl J Med [Internet]. 2001 [cited 2017 Aug 15];344(23):1773–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11396445.

  2. Callaghan MU, Kaufman RJ. Cellular processing of factor VIII and factor IX. In: Lee CA, Berntorp E, Hoots K, editors. Textbook of hemophilia. 2nd ed. Chichester/Hoboken: Wiley-Blackwell; 2010.

    Google Scholar 

  3. Zhang B, Spreafico M, Zheng C, et al. Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. Blood. 2008;111(12):5592–600.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Zia AN, Chitlur M, Rajpurkar M, et al. Thromboelastography identifies children with rare bleeding disorders and predicts bleeding phenotype. Haemophilia. 2015;21(1):124–32.

    Article  CAS  PubMed  Google Scholar 

  5. Chitlur M, Warrier I, Rajpurkar M, et al. Thromboelastography in children with coagulation factor deficiencies. Br J Haematol. 2008;142(2):250–6.

    Article  PubMed  Google Scholar 

  6. Chitlur MB, Rao LB, Callaghan MU, Rajpurkar M, Lusher JM. Thromboelastography for monitoring of hemostatic changes following factor administration. Blood. 2012;120(21):3373.

    Article  Google Scholar 

  7. Callaghan MU, Kaufman RJ. Synthesis and secretion of coagulation factor VIII. In: Tanaka K, Davie EW, Ikeda Y, et al., editors. Recent advances in thrombosis and hemostasis 2008. Tokyo: Springer; 2009. p. 45–67.

    Google Scholar 

  8. Lusher JM, Salzman PM. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. Semin Hematol. 1990;27(2 Suppl 2):1–7.

    CAS  PubMed  Google Scholar 

  9. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A – safety, efficacy, and development of inhibitors. N Engl J Med. 1993;328(7):453–9.

    Article  CAS  PubMed  Google Scholar 

  10. Lusher JM, Scharrer I. Evolution of recombinant factor VIII safety: KOGENATE® and Kogenate® FS/Bayer. Int J Hematol. 2009;90(4):446–54.

    Article  CAS  PubMed  Google Scholar 

  11. Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol. 2018;11(11):835–46.

    Article  CAS  PubMed  Google Scholar 

  12. Knight T, Callaghan MU. The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A. Ther Adv Hematol. 2018;9(10):319–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Young G, Sidonio RF, Liesner R, et al. HAVEN 2 updated analysis: multicenter, open-label, phase 3 study to evaluate efficacy, safety and pharmacokinetics of subcutaneous administration of emicizumab prophylaxis in pediatric patients with hemophilia A with inhibitors. Blood [Internet]. 2017 [cited 2018 Apr 12];130(Suppl 1):85. Available from: http://www.bloodjournal.org/content/130/Suppl_1/85.

  14. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med [Internet]. 2017 [cited 2017 Aug 9];377:809–18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28691557.

  15. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia a without inhibitors. N Engl J Med. 2018;379:811–22.

    Article  CAS  PubMed  Google Scholar 

  16. Croteau SE, Callaghan MU, Davis J, et al. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Res Pract Thromb Haemost. 2018;2(3):607–14.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Özgönenel B, Zia A, Callaghan MU, Chitlur M, Rajpurkar M, Lusher JM. Emergency department visits in children with hemophilia. Pediatr Blood Cancer. 2013;60(7):1188–91.

    Article  PubMed  Google Scholar 

  18. Soucie JM, Nuss R, Evatt B, et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood. 2000;96(2):437–42.

    CAS  PubMed  Google Scholar 

  19. Walsh CE, Jiménez-Yuste V, Auerswald G, Grancha S. The burden of inhibitors in haemophilia patients. Thromb Haemost [Internet]. 2016 [cited 2017 Aug 9];116(Suppl. 1):S10–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27528280.

  20. Callaghan MU, Rajpurkar M, Chitlur M, Warrier I, Lusher J. Immune tolerance induction in 31 children with haemophilia A: Is ITI less successful in African Americans? Haemophilia. 2011;17(3):483–9.

    Article  CAS  PubMed  Google Scholar 

  21. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med. 1980;303(8):421–5.

    Article  CAS  PubMed  Google Scholar 

  22. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 1994;55(6):638–48.

    Article  CAS  PubMed  Google Scholar 

  23. Warrier I, Ewenstein BM, Koerper MA, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. Am J Pediatr Hematol Oncol. 1997;19(1):23–7.

    Article  CAS  Google Scholar 

  24. Callaghan MU, Fogarty PF. What is the evidence for the use of immunomodulatory agents to eradicate inhibitory antibodies in patients with severe hemophilia a who have previously failed to respond to immune tolerance induction? Hematology Am Soc Hematol Educ Program. 2011;2011:405–6.

    Article  PubMed  Google Scholar 

  25. Antun A, Monahan PE, Manco-Johnson MJ, et al. Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study. J Thromb Haemost [Internet]. 2015 [cited 2016 Jan 6];13(11):1980–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26382916.

  26. Callaghan MU, Sidonio R, Pipe SW. Novel therapeutics for hemophilia and other bleeding disorders. Blood. 2018;132(1):23–30.

    Google Scholar 

  27. Callaghan M, Kaufman R. Haemophilias: gene therapy [Internet]. In: Encyclopedia of life sciences (eLS). Chichester: John Wiley & Sons, Ltd; 2009 [cited 2016 Jan 28]. Available from: http://onlinelibrary.wiley.com/doi/10.1002/9780470015902.a0005750.pub2/full.

  28. Özgönenel B, Rajpurkar M, Lusher JM. How do you treat bleeding disorders with desmopressin? Postgrad Med J. 2007;83(977):159–63.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Children’s Hospital of Michigan, Wayne State University, Detroit, MI, USA

    Michael Callaghan

Authors
  1. Michael Callaghan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Callaghan .

Editor information

Editors and Affiliations

  1. Department of Pediatrics, University of Texas Health Science Center, San Antonio, TX, USA

    Deepak M. Kamat

  2. Department of Pediatrics, Division of Hematology-Oncology, The University of Texas Health Science Center, San Antonio, TX, USA

    Melissa Frei-Jones

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Callaghan, M. (2021). Hemophilia. In: Kamat, D., Frei-Jones, M. (eds) Benign Hematologic Disorders in Children. Springer, Cham. https://doi.org/10.1007/978-3-030-49980-8_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-49980-8_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-49979-2

  • Online ISBN: 978-3-030-49980-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation